Compare Amphastar Pharmaceuticals Inc (AMPH) vs Canadian National Railway Co. (CNI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Canadian National Railway Co. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Canadian National Railway Co. trades at $126.3 (market cap $75.59B). The key difference: Canadian National Railway Co. is far larger — about 87.5× Amphastar Pharmaceuticals Inc's market cap, and Canadian National Railway Co. pays a 2.08% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CNI | |
|---|---|---|
Market Cap | $863.95M | $75.59B |
Sector | Health | Industrials |
52-Week High | $30.81 | $130.58 |
52-Week Low | $16.87 | $90.91 |
Enterprise Value | $1.26B | $91.60B |
Dividend Yield | — | 2.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Canadian National Railway (CNI) trades at $126.60, up 0.16% with neutral technical signals. The company reported strong Q2 2026 results with EPS of $1.50 beating estimates by 7.9% and raised full-year guidance. Fundamentals show solid profitability with 26.92% net margin and 22.02% ROE, though valuation appears elevated at 22.77 P/E. Recent news highlights record grain movements and over 300 customer growth projects across CN's network.
CNI presents a mixed outlook with strong operational execution offset by valuation concerns. The 20% upside to consensus price target of $152.38 offers potential, but debt levels rising to 36.61% of assets and competitive pressures warrant caution. Earnings consistency remains key with Q3 results pending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →
